AstraZeneca announced its plans to broaden its saving programs across its entire respiratory medicine portfolio in the U.S. Effective from June 1, 2024, qualified patients will be required to pay no more than $35 per month for all AstraZeneca inhalant respiratory drugs in the U.S such as AIRSUPRA, BEVESPI AEROSPHERE, BREZTRI AEROSPHERE, and SYMBICORT. The pharmaceutical giant also emphasized that it drastically cut the list price of SYMBICORT as of January 1, 2024.
Pascal Soriot, the CEO of AstraZeneca, conveyed their commitment towards addressing the financial accessibility of their medicines. He added that the present system is intricate and requires collective efforts for change. He states that the Congress's pivotal role in convening key players to consider reforming the healthcare system is imperative. Their aim is to ensure affordability of medicines for patients, not merely in the present scenario but also considering future scenarios.
For further health-related news updates, visit rttnews.com.
